If Approved, Omaveloxolone Would Become the First Therapy Indicated for the Treatment of Patients with Friedreich’s Ataxia PLANO, Texas–(BUSINESS WIRE) January 31, 2022 — Reata Pharmaceuticals, Inc. (Nasdaq: RETA),…Original Article
Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
